BlueCare Tennessee

High-Cost Lab Prior Authorization List

Code	Procedure Description
81529	ONC CUTAN MLNMA MRNA 31 GENE
81554	Culture, typing; identification of blood pathogen & resistance typing, when performed, by nucleic acid probe, multiplexed amplified probe technique including multiplex reverse
0242U	TRGT GEN SEQ ALYS PNL 55-74
0045U	Oncology, mRNA, gene expression profiling by real-time RT-PCR of 12 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score
0047U	Oncology, mRNA, gene expression profiling by real-time RT-PCR of 17 gene utilizing formalin-fixed paraffin-embedded tissue algorithm
0258U	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics
81523	Oncology, mRNA, next-generation sequencing gene expression profiling of 70 content genes & 31 housekeeping genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm
0244U	ONC THYR MUT ALYS 10 GEN&37
81521	ONC BREAST MRNA 70 GENES
0239U	TRGT GEN SEQ ALYS PNL 311+
81518	ONC BRST MRNA 11 GENES
0037U	TRGT GEN SEQ DNA 324 GENES
81546	ONC THYR MRNA 10,196 GEN ALG
0055U	Cardiology, cell-free DNA, PCR assay of 96 DNA target sequences, plasma
81519	ONCOLOGY BREAST MRNA
81440	MITOCHONDRIAL GENE
0250U	ONC SLD ORG NEO DNA 505 GENE

25PED3537250 (10/25)

Code	Procedure Description
81525	Oncology, mRNA gene expression profiling real-time RT-PCR 12 genes utilizing formalin-fixed paraffin-embedded tissue, algorithm
0048U	Oncology, DNA, targeted sequencing of protein-coding exons of 468 cancer- associated genes, including interrogation for somatic mutations & microsatellite instability, matched
0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements
81520	ONC BREAST MRNA 58 GENES
81229	CYTOG ALYS CHRML ABNR SNPCGH
81408	Mopath procedure level 9
81455	TARGETED GENOMIC SEQ ANALYSIS
81162	BRCA1&2 GEN FULL SEQ DUP/DEL
81443	GENETIC TSTG SEVERE INH COND
0053U	Oncology, FISH analysis of 4 genes, needle biopsy specimen, algorithm reported as probability of higher tumor grade
81216	BRCA2 gene analysis; full sequence analysis
81220	CFTR gene com variants
81223	CFTR gene full sequence
81298	MSH6 gene full seq
81317	PMS2 gene full seq analysis
81407	Mopath procedure level 8
81432	Hereditary breast cancer-related disorders
81432	Hereditary breast cancer-related disorders; genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH
81185	CACNA1A gene analysis; full gene sequence
0012M	Oncology, mRNA, gene expression profiling by real-time quantitative PCR of 5 genes, utilizing urine, algorithm reported as risk score for having urothelial carcinoma
0013M	Oncology, mRNA, gene expression profiling by real-time quantitative PCR of 5 genes, utilizing urine, algorithm reported as risk score for having recurrent urothelial carcinoma

Code	Procedure Description
0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
81439	Hereditary cardiomyopathy, genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes
0246U	Red blood cell antigen typing, DNA, genotyping of at least 16 blood groups with phenotype prediction of at least 51 red blood cell antigens
0282U	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes
81435	Hereditary colon cancer disorders; genomic sequence analysis panel, must include sequencing of at least 10 genes, including APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, S
81436	Hereditary colon cancer disorders; duplication/deletion gene analysis panel, must include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4, & STK11
0070U	CYP2D6 gene analysis, common & select rare variants
81448	Hereditary peripheral neuropathies, genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes
81175	ASXL1, gene analysis; full gene sequence
81292	MLH1 gene analysis; full sequence analysis
81295	MSH2 gene analysis; full sequence analysis
81406	Molecular pathology procedure, Level 7
0236U	SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2, centromeric) (e.g., spinal muscular atrophy) full gene analysis, including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions
0235U	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
0237U	Cardiac ion channelopathies (e.g., Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions

Code	Procedure Description
0238U	Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non- uniquely mappable regions
81450	Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, & RNA analysis when performed, 5-50 genes, interrogation for sequence variants
81433	Hereditary breast cancer-related disorders: duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, & STK11
81434	Hereditary retinal disorders, genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RD
81437	Hereditary neuroendocrine tumor disorders
81438	Hereditary neuroendocrine tumor disorders
81442	Noonan spectrum disorders, genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1,
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, & RNA analysis when performed, 5-50 genes, interrogation for sequence variants & copy number variance
81595	Cardiology mRNA gene expression profiling real-time quantitative PCR 20 genes util
81238	F9, full gene sequence
81249	G6PD, gene analysis; full gene sequence
81259	HBA1/HBA2, gene analysis; full gene sequence
81490	Autoimmune, analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as disease activity score
0234U	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions
81164	BRCA1, BRCA2 gene analysis; full duplication/deletion analysis

Code	Procedure Description
0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)
0326U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden
0338U	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood
0388U	Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection
0422U	Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate
0486U	Oncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction
0487U	Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy-corrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability
0490U	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood

Code	Procedure Description
0491U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood
0539U	Oncology (solid tumor), cell-free circulating tumor DNA (ctDNA), 152 genes, next-generation sequencing, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, copy number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant

25PED3537250 (10/25)